Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever
Standard
Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. / Oestereich, Lisa; Rieger, Toni; Lüdtke, Anja; Ruibal, Paula; Wurr, Stephanie; Pallasch, Elisa; Bockholt, Sabrina; Krasemann, Susanne; Muñoz-Fontela, César; Günther, Stephan.
in: J INFECT DIS, Jahrgang 213, Nr. 6, 03.2016, S. 934-948.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever
AU - Oestereich, Lisa
AU - Rieger, Toni
AU - Lüdtke, Anja
AU - Ruibal, Paula
AU - Wurr, Stephanie
AU - Pallasch, Elisa
AU - Bockholt, Sabrina
AU - Krasemann, Susanne
AU - Muñoz-Fontela, César
AU - Günther, Stephan
N1 - © The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America.
PY - 2016/3
Y1 - 2016/3
N2 - We studied the therapeutic potential of favipiravir (T-705) for Lassa fever, both alone and in combination with ribavirin. Favipiravir suppressed Lassa virus replication in cell culture by 5 log10 units. In a novel lethal mouse model, it lowered the viremia level and the virus load in organs and normalized levels of cell-damage markers. Treatment with 300 mg/kg per day, commenced 4 days after infection, when the viremia level had reached 4 log10 virus particles/mL, rescued 100% of Lassa virus-infected mice. We found a synergistic interaction between favipiravir and ribavirin in vitro and an increased survival rate and extended survival time when combining suboptimal doses in vivo.
AB - We studied the therapeutic potential of favipiravir (T-705) for Lassa fever, both alone and in combination with ribavirin. Favipiravir suppressed Lassa virus replication in cell culture by 5 log10 units. In a novel lethal mouse model, it lowered the viremia level and the virus load in organs and normalized levels of cell-damage markers. Treatment with 300 mg/kg per day, commenced 4 days after infection, when the viremia level had reached 4 log10 virus particles/mL, rescued 100% of Lassa virus-infected mice. We found a synergistic interaction between favipiravir and ribavirin in vitro and an increased survival rate and extended survival time when combining suboptimal doses in vivo.
U2 - 10.1093/infdis/jiv522
DO - 10.1093/infdis/jiv522
M3 - SCORING: Journal article
C2 - 26531247
VL - 213
SP - 934
EP - 948
JO - J INFECT DIS
JF - J INFECT DIS
SN - 0022-1899
IS - 6
ER -